{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:19:25Z","timestamp":1779315565073,"version":"3.51.4"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,8,15]]},"DOI":"10.2169\/internalmedicine.6948-20","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T22:06:28Z","timestamp":1615154788000},"page":"2659-2662","source":"Crossref","is-referenced-by-count":6,"title":["Successful Treatment of Incidental Histiocytic Sarcoma Concomitant with Laryngeal Carcinoma"],"prefix":"10.2169","volume":"60","author":[{"given":"Satoko","family":"Oka","sequence":"first","affiliation":[{"name":"Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Pathology, Japanese Red Cross Society Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Nohgawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Takahashi E, Nakamura S. Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53: 1-8, 2013.","DOI":"10.3960\/jslrt.53.1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ansari J, Naqash AR, Munker R, et al. Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol 97: 9-16, 2016.","DOI":"10.1111\/ejh.12755"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41: 1-29, 2002.","DOI":"10.1046\/j.1365-2559.2002.01418.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hornick JL, Jaffe ES, Fletcher CDM. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol 28: 1133-1144, 2004.","DOI":"10.1097\/01.pas.0000131541.95394.23"},{"key":"5","unstructured":"5. Cattoretti G, Villa A, Vezzoni P, Giardini R, Lombardi L, Rilke F. Malignant histiocytosis. A phenotypic and genotypic investigation. Am J Pathol 136: 1009-1019, 1990."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Brunner P, Rufle A, Dirnhofer S, et al. Folliular lymphoma transformation into histiocytic sarcoma: indications for a common neoplastic progenitor. Leukemia 28: 1937-1940, 2014.","DOI":"10.1038\/leu.2014.167"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Michonneau D, Kaltenbach S, Derrieux C, et al. BRAF (V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol 32: e117-e121, 2014.","DOI":"10.1200\/JCO.2013.49.0078"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Isaacson PG, O'Connor NT, Spencer J, et al. Malignant histiocytosis of the intestine: a T-cell lymphoma. Lancet 2: 688-691, 1985.","DOI":"10.1016\/S0140-6736(85)92930-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kamel OW, Gocke CD, Kell DL, Cleary ML, Warnke RA. True histiocytic lymphoma: a study of 12 cases based on current definition. Leuk Lymphoma 18: 81-86, 1995.","DOI":"10.3109\/10428199509064926"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lauritzen AF, Delsol G, Hansen NE, et al. Histiocytic sarcomas and monoblastic leukemias. A clinical, histologic, and immunophenotypical study. Am J Clin Pathol 102: 45-54, 1994.","DOI":"10.1093\/ajcp\/102.1.45"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shanmugam V, Griffin GK, Jacobsen ED, Fletcher CDM, Sholl LM, Hornick JL. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. Mod Pathol 32: 830-843, 2019.","DOI":"10.1038\/s41379-018-0200-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Broadwater DR, Conant JL, Czuchlewski DR, et al. Clinicopathologic features and clinical outcome differences in de novo versus secondary histiocytic sarcomas: a multi-institutional experience and review of the literature. Clin Lymphoma Myeloma Leuk 18: e427-e435, 2018.","DOI":"10.1016\/j.clml.2018.07.286"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gallo O, Libonati GA, Gallina E, et al. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 117: 1007-1010, 1991.","DOI":"10.1001\/archotol.1991.01870210079015"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol 82: 932-933, 2007.","DOI":"10.1002\/ajh.20913"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shukla N, Kobos R, Renaud T, et al. Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. Cancer 118: 3719-3724, 2012.","DOI":"10.1002\/cncr.26712"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Idbaih A, Mokhtari K, Emile JF, et al. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 83: 1478-1480, 2014.","DOI":"10.1212\/WNL.0000000000000880"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Abu-Sanad A, Warsi A, Michel RP, et al. Long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma. Curr Oncol 19: e289-e291, 2012.","DOI":"10.3747\/co.19.964"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/16\/60_6948-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T03:50:51Z","timestamp":1629517851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/16\/60_6948-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,15]]},"references-count":17,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6948-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,15]]},"article-number":"6948-20"}}